Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • One Drug, Multiple...

    One Drug, Multiple Manufacturing Facilities: CDSCO approves manufacturing of new drug in additional sites

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-14T16:38:57+05:30  |  Updated On 14 Sept 2019 4:38 PM IST
    One Drug, Multiple Manufacturing Facilities: CDSCO approves manufacturing of new drug in additional sites

    New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has apprised drug makers that they can manufacture a new drug in their additional manufacturing site, on condition that they establish similarity by way of technology transfer with respect to the manufacturing process.






    Confirmation to this effect has been given by Dr V G Somani, Drugs Controller General of India(DCGI) in a circular to all the stakeholders, clarifying the issue of manufacturing a new drug by a manufacturer in their own multiple manufacturing sites.


    Dr Somani said, "Requirements for manufacturing of new drug by a manufacturer in its own additional site has been under discussion for quite some times now."


    It is observed that for the generation of Chemistry Manufacturing and Control (CMC) data, the manufacturer needs to obtain a license or permission from the concerned Authority. CMC is an activity including appropriately manufacture Pharmaceutical or biologic specific manufacturing processes, product characteristics, and product testing must be defined in order to ensure that the product is safe, effective and consistent between batches.




    The matter has been examined and it has been decided that if CMC data is generated by a manufacturer in one of its manufacturing facility and based on the data, the approval has been granted to the manufacturer for manufacturing of the new drug in that facility, the same data may be utilized by the same manufacturer for manufacturing of same product in its additional manufacturing sites.


    However, this can be carried out with necessary permission or license provided that the manufacturer establishes the similarity by way of technology transfer with respect to a manufacturing process, equipment, process parameters, process capability and bridging validation for technology transfer wherever required etc. between the proposed additional manufacturing sites and the approved manufacturing site.


    Also Read: Grant of Manufacturing License for Drugs: DTAB recommends amendment of Drugs and Cosmetics Rules, 1945

    CDSCOCentral Drugs Standard Control OrganizationChemistry Manufacturing and ControlCMC dataDCGOdrug manufactureing sitedrug manufacturersdrug regulator circularDrugs Controller General of Indiamanufacturing facilitynew drugpharmapharma newspharmaceutical productspharmanews indiav g somani

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok